Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial

BACKGROUND: The treatment of recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) remains challenging. Preclinical studies revealed that B cell depletion could modulate the microenvironment and overcome chemoresistance. We conducted a phase I study to evaluate the feasibility an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ching-Yun, Lien, Ming-Yu, Lin, Chen-Yuan, Lo, Wen-Jyi, Hua, Chung-Hung, Chang, Wei-Chao, Chiu, Chang-Fang, Lin, Ching-Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845344/
https://www.ncbi.nlm.nih.gov/pubmed/35168547
http://dx.doi.org/10.1186/s12885-022-09258-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845344/
https://www.ncbi.nlm.nih.gov/pubmed/35168547
http://dx.doi.org/10.1186/s12885-022-09258-0

Ejemplares similares